Rhythm Pharmaceuticals (RYTM) Stock Analysis & AI Equity Report
Rhythm Pharmaceuticals (RYTM) overview
Rhythm Pharmaceuticals (RYTM) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 190m and operating profit of USD -192m; the year-end share price was 107.04 USD and market capitalisation was USD 7,194m. Rhythm Pharmaceuticals is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Rhythm Pharmaceuticals's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Rhythm Pharmaceuticals
Rhythm Pharmaceuticals is a biopharmaceutical company developing melanocortin-4 receptor agonists for rare neuroendocrine diseases associated with hyperphagia and severe obesity. Its marketed medicine, IMCIVREE (setmelanotide), is authorized for certain rare MC4R pathway diseases, including Bardet-Biedl syndrome and specified genetic deficiencies. The company is also developing investigational medicines bivamelagon and RM-718 for hypothalamic obesity and related conditions.
Generate the Rhythm Pharmaceuticals report
Rhythm Pharmaceuticals is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Rhythm Pharmaceuticals and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Rhythm Pharmaceuticals
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.